How Clinical Signals From Oral Zelenirstat Apply to NMT Inhibitors as ADC Payloads: Leveraging Validated Mechanisms & a Known Safety Profile
Time: 11:15 am
day: Conference Day Two
Details:
- Discussing clinical data from FIC oral NMT inhibitor, zelenirstat, including survival benefits in patients with solid tumors and clinical response in lymphoma, that support the mechanism’s therapeutic potential
- Preliminary analysis of an extensive portfolio of potent NMTi ADC candidates
- Preliminary examination of in vitro ADC data on the potential NMTi-ADC activity against cancer cell lines
